Search for Clinical Trial Results
Primary Central Nervous System Lymphoma - 27 Studies Found
Status | Study |
Recruiting |
Study Name: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Condition: Primary CNS Lymphoma Date: 2016-10-13 Interventions:
|
Active, not recruiting |
Study Name: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients Condition: Primary Central Nervous System Lymphoma Date: 2009-03-16 Interventions:
|
Recruiting |
Study Name: Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2014-12-05 Interventions: Drug: Rituximab, Methotrexate, Temozolomide Seven monthly R-MT cycles including high dose MTX (3.5g/m2, |
Recruiting |
Study Name: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Condition:
|
Recruiting |
Study Name: Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute Condition: Primary Central Nervous System Lymphoma Date: 2015-12-09 Interventions: Radiation: Standard treatment protocol with combined chemoradiation |
Enrolling by invitation |
Study Name: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Condition: Primary Central Nervous System Lymphoma Date: 2014-04-23 Interventions: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Recruiting |
Study Name: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Condition: Primary Central Nervous System Lymphoma Date: 2016-07-14 Interventions: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Terminated |
Study Name: Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2014-04-10 Interventions: Drug: Rituximab plus Temozolomide Treatment cycles will be repeated every 14 days (2 weeks) for the lead |
Completed |
Study Name: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Condition:
Interventions: Drug: Buparlisib (BKM120) Buparlisib 100 mg once daily. |
Recruiting |
Study Name: Treatment of Primary CNS Lymphoma Condition: Primary CNS Lymphoma (PCNSL) Date: 2013-10-08 Interventions:
|